About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Tcf7l2
transcription factor 7 like 2, T cell specific, HMG box
MGI:1202879
86 phenotypes from 15 alleles in 10 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Tcf7l2em1Nobr/Tcf7l2+
involves: CD-1
decreased body weight J:175874
decreased circulating glucose level J:175874
decreased circulating insulin level J:175874
decreased lean body mass J:175874
decreased total body fat amount J:175874
normal homeostasis/metabolism phenotype J:175874
hypoactivity J:175874
hypoglycemia J:175874
improved glucose tolerance J:175874
polyphagia J:175874
Tcf7l2em1Nobr/Tcf7l2em1Nobr
involves: CD-1
absent gastric milk in neonates J:175874
decreased birth body size J:175874
hypoglycemia J:175874
neonatal lethality, complete penetrance J:175874
Tcf7l2em2Nobr/Tcf7l2+
involves: CD-1
decreased body weight J:175874
decreased circulating glucose level J:175874
decreased circulating insulin level J:175874
decreased lean body mass J:175874
decreased total body fat amount J:175874
normal homeostasis/metabolism phenotype J:175874
hypoactivity J:175874
hypoglycemia J:175874
improved glucose tolerance J:175874
polyphagia J:175874
Tcf7l2em2Nobr/Tcf7l2em2Nobr
involves: CD-1
absent gastric milk in neonates J:175874
decreased birth body size J:175874
hypoglycemia J:175874
neonatal lethality, complete penetrance J:175874
Tcf7l2em3Nobr/Tcf7l2em3Nobr
involves: CD-1
absent gastric milk in neonates J:175874
decreased birth body size J:175874
hypoglycemia J:175874
neonatal lethality, complete penetrance J:175874
Tcf7l2tm1(EGFP/cre)Mrc/Tcf7l2tm2.1Mrc
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NCrl
abnormal crypts of Lieberkuhn morphology J:170088
decreased body size J:170088
normal neoplasm J:170088
Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2tm1.1(EGFP/cre)Mrc
involves: 129S1/Sv * 129X1/SvJ
abnormal colon goblet cell morphology J:170088
abnormal colon morphology J:170088
abnormal crypts of Lieberkuhn morphology J:170088
abnormal enterocyte proliferation J:170088
abnormal intestinal enteroendocrine cell morphology J:170088
abnormal intestine morphology J:170088
abnormal small intestine goblet cell morphology J:170088
abnormal small intestine morphology J:170088
absent gastric milk in neonates J:170088
decreased birth weight J:170088
embryo tissue necrosis J:170088
neonatal lethality, complete penetrance J:170088
Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2tm2.1Mrc
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NCrl
abnormal colon morphology J:170088
abnormal crypts of Lieberkuhn morphology J:170088
abnormal enterocyte proliferation J:170088
abnormal intestinal enteroendocrine cell morphology J:170088
abnormal intestinal goblet cell morphology J:170088
abnormal intestine morphology J:170088
abnormal small intestine morphology J:170088
absent gastric milk in neonates J:170088
decreased birth weight J:170088
embryo tissue necrosis J:170088
neonatal lethality, complete penetrance J:170088
Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2tm2.2Mrc
involves: 129S1/Sv * 129X1/SvJ
abnormal colon morphology J:170088
abnormal crypts of Lieberkuhn morphology J:170088
abnormal enterocyte proliferation J:170088
abnormal intestinal enteroendocrine cell morphology J:170088
abnormal intestinal goblet cell morphology J:170088
abnormal intestine morphology J:170088
abnormal small intestine morphology J:170088
absent gastric milk in neonates J:170088
decreased birth weight J:170088
embryo tissue necrosis J:170088
neonatal lethality, complete penetrance J:170088
Tcf7l2tm1a(EUCOMM)Wtsi/Tcf7l2+
C57BL/6-Tcf7l2tm1a(EUCOMM)Wtsi
abnormal glucose homeostasis J:190447
abnormal hepatocyte physiology J:190447
abnormal response/metabolism to endogenous compounds J:190447
impaired glucose tolerance J:190447
increased circulating glucose level J:190447
Tcf7l2tm1a(EUCOMM)Wtsi/Tcf7l2+
C57BL/6N-Tcf7l2tm1a(EUCOMM)Wtsi/Wtsi
decreased circulating fructosamine level J:211773
decreased total body fat amount J:211773
increased bone mineral content J:211773
increased lean body mass J:211773
Tcf7l2tm1a(EUCOMM)Wtsi/Tcf7l2tm1a(EUCOMM)Wtsi
C57BL/6-Tcf7l2tm1a(EUCOMM)Wtsi
lethality, complete penetrance J:190447
Tcf7l2tm1a(EUCOMM)Wtsi/Tcf7l2tm1a(EUCOMM)Wtsi
C57BL/6N-Tcf7l2tm1a(EUCOMM)Wtsi/Wtsi
abnormal basilar artery morphology J:239583
abnormal cecum position J:239583
abnormal elbow joint morphology J:239583
abnormal eye muscle morphology J:239583
abnormal forebrain morphology J:239583
abnormal inferior vena cava morphology J:239583
abnormal inferior vena cava topology J:239583
abnormal Mullerian duct morphology J:239583
abnormal nasal septum morphology J:239583
abnormal neurohypophysis morphology J:239583
abnormal pulmonary valve cusp morphology J:239583
abnormal umbilical vein topology J:239583
abnormal ureter topology J:239583
abnormal vertebral artery morphology J:239583
abnormal vertebral artery topology J:239583
abnormal Wolffian duct morphology J:239583
absent ductus venosus valve J:239583
absent kidney J:239583
basisphenoid bone foramen J:239583
common truncal valve J:239583
double outlet right ventricle J:239583
duplication of ductus venosus J:239583
enlarged liver sinusoidal spaces J:239583
fusion of vertebral arches J:239583
heterochrony J:239583
muscular ventricular septal defect J:239583
perimembraneous ventricular septal defect J:239583
preweaning lethality, complete penetrance J:211773
retroesophageal right subclavian artery J:239583
symmetric azygos veins J:239583
vertebral fusion J:239583
Tcf7l2tm1Cle/Tcf7l2tm1Cle
involves: 129P2/OlaHsd
abnormal craniofacial development J:86317
abnormal enterocyte morphology J:48968
abnormal intestinal epithelium morphology J:48968
abnormal pituitary intermediate lobe morphology J:86317
normal cellular phenotype J:98680
decreased enterocyte cell number J:48968
enlarged adenohypophysis J:86317
enlarged pituitary gland J:86317
neonatal lethality, complete penetrance J:48968
Tcf7l2tm1Geno/Tcf7l2tm1Geno
Tg(Pdx1-cre)89.1Dam/0
involves: C57BL/6 * CBA
decreased insulin secretion J:189204
decreased pancreatic beta cell mass J:189204
impaired glucose tolerance J:189204
increased circulating insulin level J:189204
Tcf7l2tm2.1Cle/Tcf7l2tm2.1Cle
Tg(Vil-cre/ERT2)23Syr/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
abnormal enterocyte proliferation J:185753
abnormal intestine development J:185753
abnormal small intestine goblet cell morphology J:185753
absent Paneth cells J:185753
decreased Paneth cell number J:185753
ectopic Paneth cells J:185753
increased enterocyte apoptosis J:185753
Tcf7l2tm2.2Mrc/Tcf7l2tm2.2Mrc
involves: 129S1/Sv
abnormal colon morphology J:170088
abnormal crypts of Lieberkuhn morphology J:170088
abnormal enterocyte proliferation J:170088
abnormal intestinal enteroendocrine cell morphology J:170088
abnormal intestinal goblet cell morphology J:170088
abnormal intestine morphology J:170088
abnormal small intestine morphology J:170088
absent gastric milk in neonates J:170088
decreased birth weight J:170088
embryo tissue necrosis J:170088
neonatal lethality, complete penetrance J:170088
Tg(Krt14-Tcf7l2)1Efu/0
Not Specified
abnormal epidermal layer morphology J:155012
eyelids open at birth J:155012
Tg(Krt14-Tcf7l2*)2Efu/0
Not Specified
eyelids open at birth J:155012
Tg(Krt14-Tcf7l2*)3Efu/0
Not Specified
no abnormal phenotype detected J:155012
Tg(RP11-466I19/Tcf7l2)1Nobr/0
involves: CD-1
decreased food intake J:175874
normal homeostasis/metabolism phenotype J:175874
impaired glucose tolerance J:175874

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
12/04/2018
MGI 6.13
The Jackson Laboratory